Precise Insights. Confident Decisions.
A liquid biopsy test that detects cancer activity months earlier than imaging. Clearer answers for patients. Earlier decisions for physicians.
Many patients find that uncertainty does not end. A LIQOMICS blood test gives you and your doctor a clearer molecular picture, often earlier than a scan.
If your test shows no detectable cancer DNA, that is a meaningful result. It suggests your treatment is working. Your doctor will explain what it means for your specific follow-up.
And if cancer DNA is detected, that is valuable too: it gives your doctor an early molecular signal to act on, often before symptoms or imaging would show anything.
During and after therapy
By detecting or not detecting tumor-derived DNA, the test gives your doctor a molecular indication of whether cancer is still present, even when scans look clear.
When you feel uncertain
A LIQOMICS blood test gives you and your doctor a clearer picture of what is happening, so you can make informed decisions together rather than waiting in uncertainty.
When relapse is suspected
A blood test can detect molecular signs of relapse often significantly earlier than imaging, giving you and your doctor the advantage of time for earlier intervention.
Find your test →
Lymphoma
LymphoVista monitors B-cell and Hodgkin lymphomas for early signs of relapse. →
Solid Tumor
CancerVista monitors lung, breast, colorectal, and other solid tumors. →
Not sure yet
Tell us about your diagnosis and we will help you and your doctor find the right test. →
Your path to a Liquid Biopsy
Contact us to start the conversation. We help bridge it with your doctor, who orders the test.
A routine blood draw. No surgery, no biopsy, no hospital stay.
Sequenced in our Cologne lab using next-generation sequencing.
You and your doctor review together what the result means for your care.
Questions for your Doctor
Have more questions about how the test works? Visit our FAQ page for plain-language answers.
Today's standard tools each have real limits. LIQOMICS provides ctDNA-based MRD assessment from a routine blood draw. You get a molecular signal before imaging has anything to show.
Platform
One platform, multiple tumor types. LymphoVista covers lymphomas; CancerVista extends to solid tumors. A workflow that stays simple and familiar.
Support
One clear, actionable clinical report, plus direct access to our oncologist-led team for results interpretation and reimbursement support.
Logistics
No workflow changes. Fits into a routine blood draw. We provide the collection kit, organize logistics, and deliver results in 10 to 15 working days.
Schematic representation of liquid biopsy testing compared to imaging over the time course of treatment and surveillance.
Analysis performed exclusively in Germany under EU data protection law. No molecular biology expertise required to order.
The Ordering Process
One routine blood draw. No special equipment needed.
ctDNA and MRD analysis in our Cologne lab.
A clear clinical report, ready to guide your next decision.
Bring this to your patients
Whether monitoring response during treatment, testing in clinical remission to detect early relapse, or supporting a clinical trial: the right test depends on the tumor type. LymphoVista covers lymphomas. CancerVista covers solid tumors. We also work regularly with research and pharma partners, for example to support clinical trials.
Detect MRD in B-cell and Hodgkin lymphomas. Covers (D)LBCL, follicular lymphoma, mantle cell lymphoma, and other B-cell lymphoma subtypes.
Explore LymphoVista →Monitor treatment response and early recurrence across 17 solid tumor types, including lung, breast, colorectal, prostate, bladder, and pancreatic cancer. One test, one report format, one interpretation contact.
Explore CancerVista →Custom assay development, study and clinical trial support, and data analysis for academic institutions, pharmaceutical industry, and clinical research teams. We help you with your needs. Get in touch to explore how we can work together to improve cancer outcomes.
Explore Research Services →Not sure which test applies?
I treated cancer patients and started LIQOMICS to close a gap I kept seeing. Often not knowing whether a patient is really responding to treatment.
Our Goal
The science behind liquid biopsy moves fast. We publish our findings as they emerge.
The GHSG HD21 substudy published in Blood demonstrates that LymphoVista detects ctDNA-MRD after just two cycles of chemotherapy, identifying patients at 5.3-fold higher risk of relapse and clarifying 70% of false-positive PET results.
The IMvigor011 trial is the first randomised Phase III study to prove that ctDNA-MRD testing can guide adjuvant immunotherapy decisions in muscle-invasive bladder cancer, with a 36% reduction in disease recurrence risk and 97.1% survival in MRD-negative patients who received no treatment.
LIQOMICS introduces liquidbiopsyinfo.com, a structured, evidence-based resource for liquid biopsy applications. Plus, our latest study on ctDNA-MRD in Hodgkin lymphoma is now published in Blood.
